Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 7 Thoracic 3 Other solid neoplasm 2 Gastrointestinal 2 Sarcoma 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Sarcoma 1 Neoplasms 1

Interventions

Temozolomide 62 Cyclophosphamide 60 Radiotherapy 48 Doxorubicin 36 Filgrastim 26 Radiation 24 Irinotecan 24 fludarabine 23 Gemcitabine 23 Magnetic Resonance Spectroscopy 21 Imatinib Mesylate 19 Etoposide 18 pembrolizumab 16 Cisplatin 15 Carboplatin 15 Biopsy 15 Bevacizumab 15 Specimen Handling 14 fludarabine phosphate 12 Nivolumab 12 Leucovorin 12 Ipilimumab 12 Granulocyte Colony-Stimulating Factor 12 Chemotherapy, Adjuvant 12 pazopanib 11 Vincristine 11 Ifosfamide 11 Melphalan 10 Erlotinib Hydrochloride 10 Docetaxel 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × ARQ 197 × Sarcoma × Clear all

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡